carvedilol has been researched along with Cirrhosis, Liver in 86 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In recent years, concerns have been raised on the potential adverse effects of nonselective beta-blockers, and particularly carvedilol, on renal perfusion and survival in decompensated cirrhosis with ascites." | 9.41 | Conversion of Propranolol to Carvedilol Improves Renal Perfusion and Outcome in Patients With Cirrhosis and Ascites. ( Aggelis, N; Baltayiannis, G; Christaki, M; Christodoulou, D; Despotis, G; Fillipas-Ntekouan, S; Fotopoulos, A; Kalambokis, GN; Koustousi, C; Lakkas, L; Michalis, LK; Milionis, H; Pappas, K; Sergianiti, F; Tsiakas, I; Tsiouris, S; Xourgia, X, 2021) |
| "Carvedilol is effective in the primary prophylaxis for large oesophageal varices." | 9.24 | Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial. ( Bhadoria, AS; Bhardwaj, A; Bhatia, V; Choudhary, A; Jindal, A; Kedarisetty, CK; Kumar, G; Kumar, M; Maiwall, R; Sarin, SK; Shasthry, SM; Vashishtha, C, 2017) |
| " The aim of this randomized study was to evaluate and compare the effects of carvedilol and nebivolol on the hepatic venous pressure gradient (HVPG) response in the patients with liver cirrhosis." | 9.17 | Acute and 14-day hepatic venous pressure gradient response to carvedilol and nebivolol in patients with liver cirrhosis. ( Jonaitis, L; Kupčinskas, J; Kupčinskas, L; Petrenkienė, V; Pranculis, A; Silkauskaitė, V, 2013) |
| "To assess the beneficial and harmful effects of carvedilol compared with traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices." | 8.98 | Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. ( Bendtsen, F; Gluud, LL; Hobolth, L; Jeyaraj, R; Morgan, MY; Zacharias, AP, 2018) |
| "In this prospective cohort study, 106 cirrhotic patients with high-risk esophageal varices in the derivation cohort received carvedilol prophylaxis, and completed paired measurements of hepatic venous pressure gradient, liver stiffness (LS), and spleen stiffness (SS) at the beginning and end of dose titration." | 7.91 | Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices. ( Ahn, DW; Baik, SK; Jung, YJ; Kim, D; Kim, HY; Kim, MY; Kim, W; So, YH; Woo, H, 2019) |
| "Long-term carvedilol therapy is not harmful in patients with decompensated cirrhosis and ascites." | 7.85 | Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites. ( Hayes, PC; Lockman, KA; Mallawaarachchi, N; Plevris, JN; Robertson, M; Sinha, R, 2017) |
| "Propranolol has been used as prophylaxis for variceal bleeding in patients with cirrhosis." | 6.82 | A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. ( Baik, SK; Jang, JY; Jeong, SW; Kim, DJ; Kim, MY; Kim, SG; Kim, TY; Kim, YS; Lee, B; Seo, YS; Sohn, JH; Suk, KT; Um, SH, 2016) |
| "1%) the absolute bioavailability than the S(-) form (15." | 6.67 | Disposition of carvedilol enantiomers in patients with liver cirrhosis: evidence for disappearance of stereoselective first-pass extraction. ( Gabor, M; Neugebauer, G; Reiff, K, 1992) |
| "Liver cirrhosis was induced in rats by carbon tetrachloride (CCl4) administration for 9 weeks; carvedilol was administered simultaneously in the experimental group." | 5.51 | Carvedilol improves liver cirrhosis in rats by inhibiting hepatic stellate cell activation, proliferation, invasion and collagen synthesis. ( Li, G; Li, Z; Ling, L; Meng, D; Wang, G; Zhang, C, 2019) |
| "Carvedilol has an anti-angiogenic effect on HUVECs." | 5.42 | Carvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway. ( Ding, Q; Li, Y; Tian, XG; Wang, QZ; Zhang, CQ, 2015) |
| " First-line therapies include carvedilol or propranolol to prevent variceal bleeding, lactulose for hepatic encephalopathy, combination aldosterone antagonists and loop diuretics for ascites, and terlipressin for hepatorenal syndrome." | 5.41 | Diagnosis and Management of Cirrhosis and Its Complications: A Review. ( Parikh, ND; Tapper, EB, 2023) |
| "In recent years, concerns have been raised on the potential adverse effects of nonselective beta-blockers, and particularly carvedilol, on renal perfusion and survival in decompensated cirrhosis with ascites." | 5.41 | Conversion of Propranolol to Carvedilol Improves Renal Perfusion and Outcome in Patients With Cirrhosis and Ascites. ( Aggelis, N; Baltayiannis, G; Christaki, M; Christodoulou, D; Despotis, G; Fillipas-Ntekouan, S; Fotopoulos, A; Kalambokis, GN; Koustousi, C; Lakkas, L; Michalis, LK; Milionis, H; Pappas, K; Sergianiti, F; Tsiakas, I; Tsiouris, S; Xourgia, X, 2021) |
| "Cirrhotic patients with esophageal varices and with baseline HVPG > 12 mm Hg were prospectively randomized for primary prophylaxis to receive either carvedilol (group A, n = 110) or carvedilol plus simvastatin (group B, n = 110)." | 5.34 | Hemodynamic Effects of Adding Simvastatin to Carvedilol for Primary Prophylaxis of Variceal Bleeding: A Randomized Controlled Trial. ( Arora, V; Choudhary, A; Jindal, A; Kumar, G; Sarin, SK; Vijayaraghavan, R, 2020) |
| "Carvedilol is effective in the primary prophylaxis for large oesophageal varices." | 5.24 | Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial. ( Bhadoria, AS; Bhardwaj, A; Bhatia, V; Choudhary, A; Jindal, A; Kedarisetty, CK; Kumar, G; Kumar, M; Maiwall, R; Sarin, SK; Shasthry, SM; Vashishtha, C, 2017) |
| "Cirrhotic patients with esophageal varices were randomized to carvedilol 12." | 5.19 | Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial. ( Abid, S; Azam, Z; Hamid, S; Ismail, FW; Jafri, W; Khalid, A; Munir, SM; Parkash, O; Rauf, J; Shah, HA; Subhan, A, 2014) |
| " The aim of this randomized study was to evaluate and compare the effects of carvedilol and nebivolol on the hepatic venous pressure gradient (HVPG) response in the patients with liver cirrhosis." | 5.17 | Acute and 14-day hepatic venous pressure gradient response to carvedilol and nebivolol in patients with liver cirrhosis. ( Jonaitis, L; Kupčinskas, J; Kupčinskas, L; Petrenkienė, V; Pranculis, A; Silkauskaitė, V, 2013) |
| "Patients with oesophageal varices undergoing measurement of HVPG before and under propranolol treatment (80-160 mg/day) were included." | 5.17 | Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. ( Ferlitsch, A; Heinisch, BB; Kramer, L; Payer, BA; Peck-Radosavljevic, M; Pinter, M; Reiberger, T; Schwabl, P; Trauner, M; Ulbrich, G, 2013) |
| "To assess the beneficial and harmful effects of carvedilol compared with traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices." | 4.98 | Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. ( Bendtsen, F; Gluud, LL; Hobolth, L; Jeyaraj, R; Morgan, MY; Zacharias, AP, 2018) |
| "In this prospective cohort study, 106 cirrhotic patients with high-risk esophageal varices in the derivation cohort received carvedilol prophylaxis, and completed paired measurements of hepatic venous pressure gradient, liver stiffness (LS), and spleen stiffness (SS) at the beginning and end of dose titration." | 3.91 | Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices. ( Ahn, DW; Baik, SK; Jung, YJ; Kim, D; Kim, HY; Kim, MY; Kim, W; So, YH; Woo, H, 2019) |
| "BACKGROUND Carvedilol is the first-line drug for the primary prophylaxis of variceal bleeding due to portal hypertension (PHT) in liver cirrhosis." | 3.88 | Carvedilol Ameliorates Intrahepatic Angiogenesis, Sinusoidal Remodeling and Portal Pressure in Cirrhotic Rats. ( Li, G; Ling, L; Meng, D; Wang, S; Zhang, C, 2018) |
| "Long-term carvedilol therapy is not harmful in patients with decompensated cirrhosis and ascites." | 3.85 | Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites. ( Hayes, PC; Lockman, KA; Mallawaarachchi, N; Plevris, JN; Robertson, M; Sinha, R, 2017) |
| " The aim of study was to assess the correlation between the therapeutic efficacy of carvedilol and markers of endothelial dysfunction and systemic inflammation in patients with liver cirrhosis and portal hypertension." | 3.73 | Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes. ( Bruha, R; Dousa, M; Jachymova, M; Kalab, M; Lenicek, M; Marecek, Z; Petrtyl, J; Svestka, T; Urbanek, P; Vitek, L; Zelenka, J, 2006) |
| "220 patients with known esophageal varices on upper GI endoscopy and no previous history of GI bleed were randomized to group A (Carvedilol) and group B (Propranolol)." | 3.30 | Comparison of carvedilol and propranolol for primary prophylaxis of esophageal variceal bleed in cirrhotic patients. ( Aneeza Ilyas, -; Khalid Mahmud Khan, -; Maria, -; Muhammad Adnan Iqbal, -; Muhammad Farooq Hanif, -; Nooman Gilani, -; Raja Omer Fiaz, -, 2023) |
| "Portal hypertension is the primary driver of decompensation, including the development of ascites, hepatic encephalopathy and variceal haemorrhage." | 3.01 | Review article: controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis. ( Gillespie, SL; Hanrahan, TP; Hayes, PC; Majumdar, A; Rockey, DC, 2023) |
| "Carvedilol is a non-selective beta-blocker (NSBB) acting on hyperdynamic circulation/splanchnic vasodilation and on intrahepatic resistance." | 3.01 | Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension. ( La Mura, V; Reiberger, T; Turco, L; Vitale, G, 2023) |
| "Ivabradine combined with carvedilol improves LVDD, achieves THR more often and reduces risk of encephalopathy, acute kidney injury with improved survival in patients with cirrhosis." | 2.94 | Carvedilol Combined With Ivabradine Improves Left Ventricular Diastolic Dysfunction, Clinical Progression, and Survival in Cirrhosis. ( Goyal, R; Khumuckham, JS; Kumar, G; Premkumar, M; Rangegowda, D; Sarin, SK; Shasthry, SM; Thomas, SS; Vyas, T, 2020) |
| "Propranolol has been used as prophylaxis for variceal bleeding in patients with cirrhosis." | 2.82 | A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. ( Baik, SK; Jang, JY; Jeong, SW; Kim, DJ; Kim, MY; Kim, SG; Kim, TY; Kim, YS; Lee, B; Seo, YS; Sohn, JH; Suk, KT; Um, SH, 2016) |
| "Carvedilol is a non-selective β-blocker with intrinsic anti-α(1)-adrenergic activity, potentially more effective than propranolol in reducing hepatic venous pressure gradient (HVPG)." | 2.77 | Carvedilol or propranolol in portal hypertension? A randomized comparison. ( Bendtsen, F; Feldager Hansen, E; Grønbæk, H; Hobolth, L; Møller, S; Roelsgaard, K, 2012) |
| "Carvedilol is a nonselective beta-blocker with alpha(1)-adrenergic blocking activity." | 2.71 | Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis. ( Hou, MC; Huang, YT; Lee, FY; Lee, SD; Lin, HC; Yang, YY, 2004) |
| "Portal hypertension is the result of increased hepatic resistance and portal influx." | 2.71 | The effects of carvedilol a nonselective beta-blocker on portal hemodynamics in cirrhosis. ( Andronescu, D; Dragomir, P; Fierbinteanu-Braticevici, C; Udeanu, M, 2003) |
| "Short-term carvedilol administration is more powerful than propranolol in decreasing hepatic venous pressure gradient (HVPG) in cirrhotic patients, but induces arterial hypotension that may prevent its long-term use in portal hypertensive patients." | 2.70 | Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. ( Abraldes, JG; Albillos, A; Bañares, R; Bosch, J; De Diego, A; García-Pagán, JC; Lampreave, JL; Matilla, A; Moitinho, E; Piera, C, 2002) |
| " Chronic administration resulted in a further fall in the hepatic venous pressure gradient from a baseline of 16." | 2.70 | Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension. ( Hayes, PC; Lui, HF; Stanley, AJ; Therapondos, G; Tripathi, D, 2002) |
| "Carvedilol is a relatively safe, effective portal hypotensive agent, both acutely and over 7 days, but not superior to propranolol, at least in Indians." | 2.70 | Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics. ( Biswas, PK; Das, D; De, BK; Maity, AK; Majumdar, D; Mandal, SK; Sen, S, 2002) |
| "1%) the absolute bioavailability than the S(-) form (15." | 2.67 | Disposition of carvedilol enantiomers in patients with liver cirrhosis: evidence for disappearance of stereoselective first-pass extraction. ( Gabor, M; Neugebauer, G; Reiff, K, 1992) |
| "Frequently, relevant liver fibrosis is diagnosed by non-invasive methods (e." | 2.58 | [Management of compensated liver cirrhosis 2018 - Evidence based prophylactic measures]. ( Benten, D; Karkmann, K; Kluwe, J; Piecha, F; Rünzi, AC; Schulz, L; von Wulffen, M; Wege, H, 2018) |
| "Once gastroesophageal varices have developed, non-selective beta-blockers remain the cornerstone of therapy." | 2.55 | Prevention and treatment of variceal haemorrhage in 2017. ( Berzigotti, A; Bosch, J; Brunner, F, 2017) |
| "Carvedilol is a nonselective beta-blocker with a mild anti-alfa-1-adrenergic activity." | 2.50 | Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. ( D'Amico, G; D'Amico, M; Perricone, G; Sinagra, E; Tinè, F, 2014) |
| "Treatment with carvedilol had an inverse relation with SDANN." | 1.91 | Heart rate variability is associated with disease severity and portal hypertension in cirrhosis. ( Amodio, E; Basso, MG; Cabibbo, G; Calvaruso, V; Casuccio, A; Craxì, A; Daidone, M; Di Raimondo, D; Licata, M; Miceli, G; Pennisi, G; Petta, S; Pinto, A; Pintus, C; Simone, F; Tuttolomondo, A; Velardo, M, 2023) |
| "Although liver cirrhosis complicated with chylothorax is rare, several case reports have shown all patients with chylothorax caused by liver cirrhosis were transudative." | 1.72 | [Transudative chylothorax complicated with liver cirrhosis due to primary biliary cholangitis:case report]. ( Higashizawa, T; Hisatake, Y; Kitagawa, K; Kondo, M; Noda, M; Okamura, Y; Sekine, C; Sunaga, S; Teramoto, K, 2022) |
| "Incident ascites was associated with increased risk of death, HR 27." | 1.72 | Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans. ( Mazumder, N; Parikh, ND; Tapper, EB; Zhao, Z, 2022) |
| "Carvedilol is a nonselective beta-blocker used to reduce portal hypertension." | 1.51 | Carvedilol Inhibits Angiotensin II-Induced Proliferation and Contraction in Hepatic Stellate Cells through the RhoA/Rho-Kinase Pathway. ( Li, Z; Wang, S; Wu, Y; Xiu, A; Zhang, C, 2019) |
| "Liver cirrhosis was induced in rats by carbon tetrachloride (CCl4) administration for 9 weeks; carvedilol was administered simultaneously in the experimental group." | 1.51 | Carvedilol improves liver cirrhosis in rats by inhibiting hepatic stellate cell activation, proliferation, invasion and collagen synthesis. ( Li, G; Li, Z; Ling, L; Meng, D; Wang, G; Zhang, C, 2019) |
| "Carvedilol has been identified as a promising agent for the treatment of liver fibrosis." | 1.48 | Carvedilol attenuates liver fibrosis by suppressing autophagy and promoting apoptosis in hepatic stellate cells. ( Li, Z; Ling, L; Meng, D; Wang, G; Wu, Y; Zhang, C, 2018) |
| "Carvedilol is a drug of choice in treatment of portal hypertension." | 1.46 | Antifibrotic Effects of Carvedilol and Impact of Liver Fibrosis on Carvedilol Pharmacokinetics in a Rat model. ( Abdel-Sattar, SA; El-Bakly, WM; El-Demerdash, E; Mohamed, EA, 2017) |
| "Carvedilol has an anti-angiogenic effect on HUVECs." | 1.42 | Carvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway. ( Ding, Q; Li, Y; Tian, XG; Wang, QZ; Zhang, CQ, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (4.65) | 18.2507 |
| 2000's | 9 (10.47) | 29.6817 |
| 2010's | 43 (50.00) | 24.3611 |
| 2020's | 30 (34.88) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, Q | 1 |
| Zhou, Y | 1 |
| Xu, M | 1 |
| Liang, X | 1 |
| Jing, H | 1 |
| Wang, X | 1 |
| Li, N | 1 |
| Jindal, A | 4 |
| Sarin, SK | 5 |
| Kumar, M | 2 |
| Kumar, G | 4 |
| Tapper, EB | 3 |
| Zhao, Z | 1 |
| Mazumder, N | 1 |
| Parikh, ND | 2 |
| Dunne, PDJ | 1 |
| Young, D | 1 |
| Chuah, CS | 2 |
| Hayes, PC | 10 |
| Tripathi, D | 6 |
| Leithead, J | 1 |
| Smith, LA | 1 |
| Gaya, DR | 1 |
| Forrest, E | 2 |
| Stanley, AJ | 4 |
| Sunaga, S | 1 |
| Okamura, Y | 1 |
| Kondo, M | 1 |
| Kitagawa, K | 1 |
| Noda, M | 1 |
| Hisatake, Y | 1 |
| Teramoto, K | 1 |
| Higashizawa, T | 1 |
| Sekine, C | 1 |
| Villanueva, C | 4 |
| Torres, F | 3 |
| Shah, HA | 2 |
| Brujats, A | 1 |
| Rodrigues, SG | 1 |
| Bhardwaj, A | 2 |
| Azam, Z | 2 |
| Abid, S | 2 |
| Alvarado, E | 2 |
| Bosch, J | 10 |
| Kimer, N | 1 |
| Hobolth, L | 5 |
| Jachs, M | 1 |
| Hartl, L | 1 |
| Simbrunner, B | 1 |
| Bauer, D | 1 |
| Paternostro, R | 1 |
| Balcar, L | 1 |
| Hofer, B | 1 |
| Pfisterer, N | 1 |
| Schwarz, M | 1 |
| Scheiner, B | 1 |
| Stättermayer, AF | 1 |
| Pinter, M | 3 |
| Trauner, M | 3 |
| Mandorfer, M | 3 |
| Reiberger, T | 6 |
| Serper, M | 1 |
| Kaplan, DE | 1 |
| Taddei, TH | 1 |
| Cohen, JB | 1 |
| Mahmud, N | 1 |
| Berthier, J | 1 |
| Pasquet, A | 1 |
| Guerard, P | 1 |
| Matheux, A | 1 |
| McPhail, MJW | 1 |
| Patel, VC | 1 |
| Carter, B | 1 |
| Gillespie, SL | 2 |
| Hanrahan, TP | 1 |
| Rockey, DC | 1 |
| Majumdar, A | 1 |
| Miceli, G | 1 |
| Calvaruso, V | 1 |
| Casuccio, A | 1 |
| Pennisi, G | 1 |
| Licata, M | 1 |
| Pintus, C | 1 |
| Basso, MG | 1 |
| Velardo, M | 1 |
| Daidone, M | 1 |
| Amodio, E | 1 |
| Petta, S | 1 |
| Simone, F | 1 |
| Cabibbo, G | 1 |
| Di Raimondo, D | 1 |
| Craxì, A | 1 |
| Pinto, A | 1 |
| Tuttolomondo, A | 1 |
| Turco, L | 1 |
| Vitale, G | 1 |
| La Mura, V | 1 |
| Dai, EH | 1 |
| Guo, XR | 1 |
| Wang, JT | 1 |
| Hu, QG | 1 |
| Li, JH | 1 |
| Tang, QY | 1 |
| Zu, HM | 1 |
| Huan, H | 1 |
| Wang, Y | 1 |
| Gao, YF | 1 |
| Hu, GQ | 1 |
| Li, W | 1 |
| Liu, ZJ | 1 |
| Ma, QP | 1 |
| Song, YL | 1 |
| Yang, JH | 1 |
| Zhu, Y | 1 |
| Huang, SD | 1 |
| Meng, ZJ | 1 |
| Bai, B | 1 |
| Chen, YP | 1 |
| Gao, C | 1 |
| Huang, MX | 1 |
| Jin, SQ | 1 |
| Lu, MZ | 1 |
| Xu, Z | 1 |
| Zhang, QH | 1 |
| Zheng, S | 1 |
| Zeng, QL | 1 |
| Qi, XL | 1 |
| Muhammad Farooq Hanif, - | 1 |
| Raja Omer Fiaz, - | 1 |
| Muhammad Adnan Iqbal, - | 1 |
| Aneeza Ilyas, - | 1 |
| Maria, - | 1 |
| Khalid Mahmud Khan, - | 1 |
| Nooman Gilani, - | 1 |
| Moctezuma-Velazquez, C | 1 |
| Abraldes, JG | 3 |
| Huang, X | 1 |
| Fan, X | 1 |
| Chen, S | 1 |
| Chen, WC | 2 |
| Hou, MC | 3 |
| Wu, Y | 2 |
| Li, Z | 3 |
| Wang, S | 2 |
| Xiu, A | 1 |
| Zhang, C | 4 |
| Tian, X | 2 |
| Zhao, H | 1 |
| Guo, Z | 1 |
| Vijayaraghavan, R | 1 |
| Arora, V | 1 |
| Choudhary, A | 2 |
| Kalambokis, GN | 1 |
| Christaki, M | 1 |
| Tsiakas, I | 1 |
| Despotis, G | 1 |
| Fillipas-Ntekouan, S | 1 |
| Fotopoulos, A | 1 |
| Tsiouris, S | 1 |
| Xourgia, X | 1 |
| Lakkas, L | 1 |
| Pappas, K | 1 |
| Michalis, LK | 1 |
| Sergianiti, F | 1 |
| Baltayiannis, G | 1 |
| Christodoulou, D | 1 |
| Koustousi, C | 1 |
| Aggelis, N | 1 |
| Milionis, H | 1 |
| McDowell, HR | 1 |
| Forrest, EH | 2 |
| Ttl Tjwa, E | 1 |
| Wijarnpreecha, K | 1 |
| Li, F | 1 |
| Taner, CB | 1 |
| Yang, L | 1 |
| Tao, C | 1 |
| Zhao, C | 1 |
| Guo, J | 1 |
| Xie, S | 1 |
| Yin, F | 1 |
| Huo, X | 1 |
| Zhang, X | 1 |
| Sinha, R | 2 |
| Lockman, KA | 2 |
| Plevris, JN | 2 |
| Brito-Azevedo, A | 1 |
| Lo, GH | 1 |
| Kim, SG | 2 |
| Sohn, JH | 2 |
| Püspök, A | 1 |
| Schoder, M | 1 |
| Baumann-Durchschein, F | 1 |
| Bucsics, T | 1 |
| Datz, C | 1 |
| Dolak, W | 1 |
| Ferlitsch, A | 3 |
| Finkenstedt, A | 1 |
| Graziadei, I | 1 |
| Hametner, S | 1 |
| Karnel, F | 1 |
| Krones, E | 1 |
| Maieron, A | 1 |
| Peck-Radosavljevic, M | 3 |
| Rainer, F | 1 |
| Schwabl, P | 2 |
| Stadlbauer, V | 1 |
| Stauber, R | 1 |
| Tilg, H | 1 |
| Zoller, H | 1 |
| Schöfl, R | 1 |
| Fickert, P | 1 |
| Baiges, A | 1 |
| Hernández-Gea, V | 1 |
| Karkmann, K | 1 |
| Piecha, F | 1 |
| Rünzi, AC | 1 |
| Schulz, L | 1 |
| von Wulffen, M | 1 |
| Benten, D | 1 |
| Kluwe, J | 1 |
| Wege, H | 1 |
| Robertson, M | 2 |
| Hayes, P | 2 |
| Zacharias, AP | 1 |
| Jeyaraj, R | 1 |
| Bendtsen, F | 3 |
| Gluud, LL | 1 |
| Morgan, MY | 1 |
| Meng, D | 3 |
| Wang, G | 2 |
| Ling, L | 3 |
| Kim, HY | 1 |
| So, YH | 1 |
| Kim, W | 1 |
| Ahn, DW | 1 |
| Jung, YJ | 1 |
| Woo, H | 1 |
| Kim, D | 1 |
| Kim, MY | 2 |
| Baik, SK | 2 |
| Li, G | 2 |
| Hsin, IF | 1 |
| Chen, PH | 1 |
| Hsu, PI | 1 |
| Wang, YP | 1 |
| Cheng, JS | 1 |
| Lin, HS | 1 |
| Lee, FY | 2 |
| Albillos, A | 2 |
| Genescà, J | 1 |
| Garcia-Pagan, JC | 3 |
| Calleja, JL | 1 |
| Aracil, C | 1 |
| Bañares, R | 3 |
| Morillas, RM | 1 |
| Poca, M | 1 |
| Peñas, B | 1 |
| Augustin, S | 1 |
| Premkumar, M | 1 |
| Rangegowda, D | 1 |
| Vyas, T | 1 |
| Khumuckham, JS | 1 |
| Shasthry, SM | 2 |
| Thomas, SS | 1 |
| Goyal, R | 1 |
| Hansen, EF | 1 |
| Møller, S | 3 |
| Rauf, J | 1 |
| Hamid, S | 1 |
| Jafri, W | 1 |
| Khalid, A | 1 |
| Ismail, FW | 1 |
| Parkash, O | 1 |
| Subhan, A | 1 |
| Munir, SM | 1 |
| Sinagra, E | 1 |
| Perricone, G | 1 |
| D'Amico, M | 1 |
| Tinè, F | 1 |
| D'Amico, G | 1 |
| Silkauskaitė, V | 1 |
| Kupčinskas, J | 1 |
| Pranculis, A | 1 |
| Jonaitis, L | 1 |
| Petrenkienė, V | 1 |
| Kupčinskas, L | 1 |
| Ding, Q | 1 |
| Tian, XG | 1 |
| Li, Y | 1 |
| Wang, QZ | 1 |
| Zhang, CQ | 1 |
| Muñoz-Ortega, MH | 1 |
| Llamas-Ramírez, RW | 1 |
| Romero-Delgadillo, NI | 1 |
| Elías-Flores, TG | 1 |
| Tavares-Rodríguez, Ede J | 1 |
| Campos-Esparza, Mdel R | 1 |
| Cervantes-García, D | 1 |
| Muñoz-Fernández, L | 1 |
| Gerardo-Rodríguez, M | 1 |
| Ventura-Juárez, J | 1 |
| Araújo Júnior, RF | 1 |
| Garcia, VB | 1 |
| Leitão, RF | 1 |
| Brito, GA | 1 |
| Miguel, Ede C | 1 |
| Guedes, PM | 1 |
| de Araújo, AA | 1 |
| Li, T | 1 |
| Ke, W | 1 |
| Sun, P | 1 |
| Chen, X | 1 |
| Belgaumkar, A | 1 |
| Huang, Y | 1 |
| Xian, W | 1 |
| Li, J | 1 |
| Zheng, Q | 1 |
| Kedarisetty, CK | 1 |
| Vashishtha, C | 1 |
| Bhadoria, AS | 1 |
| Maiwall, R | 1 |
| Bhatia, V | 1 |
| Kim, TY | 1 |
| Um, SH | 1 |
| Seo, YS | 1 |
| Jang, JY | 1 |
| Jeong, SW | 1 |
| Lee, B | 1 |
| Kim, YS | 1 |
| Suk, KT | 1 |
| Kim, DJ | 1 |
| El-Demerdash, E | 2 |
| Abdel-Sattar, SA | 1 |
| El-Bakly, WM | 1 |
| Mohamed, EA | 1 |
| Brunner, F | 1 |
| Berzigotti, A | 1 |
| Mallawaarachchi, N | 1 |
| Steib, CJ | 1 |
| Gerbes, AL | 1 |
| Tsochatzis, EA | 1 |
| Triantos, CK | 1 |
| Burroughs, AK | 1 |
| Hussain, Q | 1 |
| Badruddin, AH | 1 |
| Chaudhry, MA | 1 |
| Ahmad, F | 1 |
| Abbasi, A | 1 |
| Payer, BA | 2 |
| Homoncik, M | 1 |
| Grønbæk, H | 1 |
| Roelsgaard, K | 1 |
| Feldager Hansen, E | 1 |
| Liu, J | 1 |
| Takase, I | 1 |
| Hakucho, A | 1 |
| Okamura, N | 1 |
| Fujimiya, T | 1 |
| Hamdy, N | 1 |
| Bonefeld, K | 1 |
| Juul, A | 1 |
| Ulbrich, G | 1 |
| Heinisch, BB | 1 |
| Kramer, L | 1 |
| Moitinho, E | 2 |
| Matilla, A | 1 |
| Lampreave, JL | 1 |
| Piera, C | 1 |
| De Diego, A | 2 |
| Lin, HC | 1 |
| Yang, YY | 1 |
| Huang, YT | 1 |
| Lee, SD | 1 |
| Fierbinteanu-Braticevici, C | 1 |
| Udeanu, M | 1 |
| Dragomir, P | 1 |
| Andronescu, D | 1 |
| Bruha, R | 1 |
| Vitek, L | 1 |
| Petrtyl, J | 1 |
| Lenicek, M | 1 |
| Urbanek, P | 1 |
| Zelenka, J | 1 |
| Jachymova, M | 1 |
| Svestka, T | 1 |
| Kalab, M | 1 |
| Dousa, M | 1 |
| Marecek, Z | 1 |
| Bouchier, IA | 1 |
| Therapondos, G | 2 |
| Helmy, A | 1 |
| Piqueras, B | 1 |
| Casado, M | 1 |
| Stanley, A | 1 |
| Wong, F | 1 |
| Blendis, L | 1 |
| Lui, HF | 1 |
| De, BK | 1 |
| Das, D | 1 |
| Sen, S | 1 |
| Biswas, PK | 1 |
| Mandal, SK | 1 |
| Majumdar, D | 1 |
| Maity, AK | 1 |
| Neugebauer, G | 1 |
| Gabor, M | 1 |
| Reiff, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Randomized Study to Compare the Efficacy and Safety of Carvedilol With or Without Simvastatin in Patients With Portal Hypertension and Esophageal Varices[NCT02465645] | 220 participants (Actual) | Interventional | 2015-06-01 | Completed | |||
| A Prospective Multicenter Cohort Study on the Timing of Emergency Endoscopy for Esophagogastric Variceal Bleeding in Cirrhosis[NCT04932200] | 608 participants (Anticipated) | Observational | 2021-06-15 | Not yet recruiting | |||
| Timing of Endoscopic Intervention in Patients With Cirrhosis With Acute Variceal Upper Gastrointestinal Hemorrhage (TEACH Trial): a Randomized Clinical Trial[NCT04786743] | 400 participants (Anticipated) | Interventional | 2021-04-20 | Recruiting | |||
| Prospective Cohort Study to Evaluate Long-term Outcomes in Patients With Liver Cirrhosis of Boramae Hospital[NCT01943318] | 500 participants (Actual) | Observational [Patient Registry] | 2013-01-31 | Completed | |||
| Spleen Stiffness Combined With Liver Stiffness Measured by Two-dimensional Shear Wave Elastography for the Screening of High-risk Varices in Patients With Compensated Advanced Chronic Liver Disease (CHESS2004)[NCT04546360] | 300 participants (Anticipated) | Observational [Patient Registry] | 2020-09-08 | Recruiting | |||
| Carvedilol Plus Endoscopic Cyanoacrylate Injection Versus Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding[NCT02504723] | Phase 4 | 121 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| A Novel Algorithm to Stratify Clinical Decompensation Risk in Patients With Compensated Advanced Chronic Liver Disease (CHESS2108)[NCT05100485] | 1,000 participants (Actual) | Observational | 2022-01-01 | Completed | |||
| Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension[NCT01059396] | Phase 4 | 201 participants (Actual) | Interventional | 2010-01-28 | Completed | ||
| CHESS-SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease: an International Multicenter Study (CHESS2102)[NCT04975477] | 1,000 participants (Anticipated) | Observational | 2021-07-16 | Not yet recruiting | |||
| Efficacy of Carvedilol + Ivabradine vs Carvedilol Alone for Left Ventricular Diastolic Dysfunction in Chronic Liver Disease Patients and Its' Impact on Morbidity and Mortality; a Prospective Randomized Controlled Trial.[NCT04111133] | 130 participants (Anticipated) | Interventional | 2020-01-01 | Recruiting | |||
| Therapeutic Approach to Diastolic Dysfunction in Chronic Liver Disease Patients and Its' Impact on Morbidity and Mortality[NCT02294292] | 189 participants (Actual) | Interventional | 2014-07-01 | Completed | |||
| Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis: a Prospective Cohort Study[NCT04543643] | Phase 3 | 288 participants (Anticipated) | Interventional | 2021-11-01 | Not yet recruiting | ||
| A Prospective, Double-blind, Randomized Placebo-controlled Trial of Carvedilol for Early Primary Prophylaxis of Esophageal Varices in Cirrhosis.[NCT01196507] | 140 participants (Actual) | Interventional | 2010-11-30 | Completed | |||
| Transient Elastography (FibroTouch) for Assessing Risk of Gastroesophageal Varices Bleeding in Patients With Compensated Cirrhosis (Pan-CHESS1801): An International Multicenter Study[NCT03778775] | 200 participants (Anticipated) | Observational | 2018-12-14 | Recruiting | |||
| Prevalence of Metabolic Associated Fatty Liver Disease in Patients With Type 2 Diabetes in Jiangsu Province of China: a Prospective, Multicenter, Real-world Study[NCT05597709] | 2,900 participants (Anticipated) | Observational | 2022-07-01 | Recruiting | |||
| Detachable String Magnetically Controlled Capsule Endoscopy for Detecting High-risk Varices in Compensated Advanced Chronic Liver Disease (CHESS1801): A Prospective Multicenter Study[NCT03749954] | 105 participants (Actual) | Observational | 2018-11-09 | Active, not recruiting | |||
| Hemodynamic Effect of the Combination of Simvastatin With Non-cardioselective Beta Blockers in Patients With Cirrhosis and Clinically Significant Portal Hypertension[NCT01282385] | Phase 4 | 60 participants (Anticipated) | Interventional | 2011-04-30 | Not yet recruiting | ||
| Danish Carvedilol Study in Portal Hypertension. Carvedilol in the Prevention of Bleeding in Portal Hypertension and Esophageal Varices[NCT00493480] | Phase 3 | 40 participants (Anticipated) | Interventional | 2003-09-30 | Completed | ||
| Pilot Study to Evaluate the Correlation Between ¹³C Methacetin Breath Test (MBT) and HVPG Measurement as a Tool for Identifying Responders to Portal Hypertension Therapy[NCT01851252] | Phase 1 | 19 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
All adverse effects during the study period (NCT02504723)
Timeframe: Within 6 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Cyanoacrylate Injection Plus Carvedilol | 32 |
| Cyanoacrylate Injection | 9 |
All cause mortality or liver transplantation during the study period (NCT02504723)
Timeframe: Within 6 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Cyanoacrylate Injection Plus Carvedilol | 13 |
| Cyanoacrylate Injection | 20 |
All upper gastrointestinal bleeding during the follow-up period (NCT02504723)
Timeframe: Within 6 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Cyanoacrylate Injection Plus Carvedilol | 17 |
| Cyanoacrylate Injection | 29 |
Rebleeding from gastric varices during the follow-up period (NCT02504723)
Timeframe: Within 6 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Cyanoacrylate Injection Plus Carvedilol | 14 |
| Cyanoacrylate Injection | 21 |
13 reviews available for carvedilol and Cirrhosis, Liver
| Article | Year |
|---|---|
Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.
Topics: Adrenergic beta-Antagonists; Ascites; Carvedilol; Esophageal and Gastric Varices; Humans; Hypertensi | 2022 |
Carvedilol in patients with compensated cirrhosis: The ongoing benefits of definitive randomised trials over meta-analysis in patients with small varices.
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Lo | 2023 |
Review article: controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis.
Topics: Adrenergic beta-Antagonists; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal H | 2023 |
Reply to: "Carvedilol in patients with compensated cirrhosis: The ongoing benefits of definitive randomised trials over meta-analysis in patients with small varices".
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Lo | 2023 |
Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension.
Topics: Adrenergic beta-Antagonists; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal H | 2023 |
Diagnosis and Management of Cirrhosis and Its Complications: A Review.
Topics: Adult; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatic Enc | 2023 |
Pharmacologic prevention of variceal bleeding and rebleeding.
Topics: Adrenergic beta-Antagonists; Atorvastatin; Carbazoles; Carvedilol; Esophageal and Gastric Varices; G | 2018 |
[Management of compensated liver cirrhosis 2018 - Evidence based prophylactic measures].
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Germany; Hepatic Encephalop | 2018 |
Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices.
Topics: Adrenergic beta-Antagonists; Adult; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hem | 2018 |
Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Hemodynamics; Hepatic Veins; Humans; Hypertensi | 2014 |
Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis.
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Esophageal and Ga | 2016 |
Beta blockers and cirrhosis, 2016.
Topics: Acute Kidney Injury; Adrenergic beta-Antagonists; Ascites; Carbazoles; Carvedilol; Esophageal and Ga | 2017 |
Prevention and treatment of variceal haemorrhage in 2017.
Topics: Adrenergic beta-Antagonists; Anti-Bacterial Agents; Balloon Occlusion; Carbazoles; Carvedilol; Endos | 2017 |
25 trials available for carvedilol and Cirrhosis, Liver
| Article | Year |
|---|---|
Carvedilol versus endoscopic band ligation for secondary prophylaxis of variceal bleeding-long-term follow-up of a randomised control trial.
Topics: Carvedilol; Esophageal and Gastric Varices; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; | 2022 |
Comparison of carvedilol and propranolol for primary prophylaxis of esophageal variceal bleed in cirrhotic patients.
Topics: Adrenergic beta-Antagonists; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage | 2023 |
Hemodynamic Effects of Adding Simvastatin to Carvedilol for Primary Prophylaxis of Variceal Bleeding: A Randomized Controlled Trial.
Topics: Adrenergic beta-Antagonists; Adult; Carvedilol; Drug Therapy, Combination; Esophageal and Gastric Va | 2020 |
Conversion of Propranolol to Carvedilol Improves Renal Perfusion and Outcome in Patients With Cirrhosis and Ascites.
Topics: Ascites; Carvedilol; Humans; Kidney; Liver Cirrhosis; Perfusion; Propranolol | 2021 |
Carvedilol is associated with improved survival in patients with cirrhosis: a long-term follow-up study.
Topics: Adrenergic beta-Antagonists; Carvedilol; Esophageal and Gastric Varices; Follow-Up Studies; Gastroin | 2021 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
Carvedilol Combined With Ivabradine Improves Left Ventricular Diastolic Dysfunction, Clinical Progression, and Survival in Cirrhosis.
Topics: Carvedilol; End Stage Liver Disease; Humans; Ivabradine; Liver Cirrhosis; Severity of Illness Index | 2020 |
Carvedilol Combined With Ivabradine Improves Left Ventricular Diastolic Dysfunction, Clinical Progression, and Survival in Cirrhosis.
Topics: Carvedilol; End Stage Liver Disease; Humans; Ivabradine; Liver Cirrhosis; Severity of Illness Index | 2020 |
Carvedilol Combined With Ivabradine Improves Left Ventricular Diastolic Dysfunction, Clinical Progression, and Survival in Cirrhosis.
Topics: Carvedilol; End Stage Liver Disease; Humans; Ivabradine; Liver Cirrhosis; Severity of Illness Index | 2020 |
Carvedilol Combined With Ivabradine Improves Left Ventricular Diastolic Dysfunction, Clinical Progression, and Survival in Cirrhosis.
Topics: Carvedilol; End Stage Liver Disease; Humans; Ivabradine; Liver Cirrhosis; Severity of Illness Index | 2020 |
Effects of carvedilol and propranolol on circulatory regulation and oxygenation in cirrhosis: a randomised study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Arteries; Blood Pressure; Bloo | 2014 |
Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; | 2014 |
Acute and 14-day hepatic venous pressure gradient response to carvedilol and nebivolol in patients with liver cirrhosis.
Topics: Aged; Antihypertensive Agents; Benzopyrans; Carbazoles; Carvedilol; Ethanolamines; Female; Humans; H | 2013 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis.
Topics: Adult; Antihypertensive Agents; Ascites; Carbazoles; Carvedilol; End Stage Liver Disease; Esophageal | 2016 |
Gastrointestinal bleeding: Carvedilol-the best beta-blocker for primary prophylaxis?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Endoscopy; Esophageal and Gastric Varices; Gast | 2009 |
Effect of carvedilol on portal pressure estimated by hepatic vein Doppler ultrasound waveform and damping index in cirrhotic patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Flow Velocity; Carbazoles; Carvedilol; Female; Hepat | 2010 |
Carvedilol or propranolol in portal hypertension? A randomized comparison.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Fema | 2012 |
The insulin like growth factor system in cirrhosis. Relation to changes in body composition following adrenoreceptor blockade.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Body Composition; Bone Density; Car | 2012 |
Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; | 2013 |
Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis.
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Drug Therapy, Combination; Female; Humans; Hyperten | 2002 |
Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis.
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Drug Therapy, Combination; Female; Humans; Hyperten | 2004 |
The effects of carvedilol a nonselective beta-blocker on portal hemodynamics in cirrhosis.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Female; Hemodynamics; Humans; Hype | 2003 |
Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Hemodynamics; Hemorrhage; | 1999 |
Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; | 1999 |
Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension.
Topics: Carbazoles; Carvedilol; Drug Administration Schedule; Female; Hemodynamics; Humans; Hypertension, Po | 2002 |
Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Carbazole | 2002 |
Disposition of carvedilol enantiomers in patients with liver cirrhosis: evidence for disappearance of stereoselective first-pass extraction.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Biological Availability; Carbazoles; | 1992 |
48 other studies available for carvedilol and Cirrhosis, Liver
| Article | Year |
|---|---|
Sequential delivery for hepatic fibrosis treatment based on carvedilol loaded star-like nanozyme.
Topics: Carvedilol; Extracellular Matrix; Hepatic Stellate Cells; Humans; Liver Cirrhosis; Up-Regulation | 2022 |
Clinical Outcomes in Patients with Advanced Chronic Liver Disease and Hepatic Venous Pressure Gradient ≤ 10 mm Hg.
Topics: Carvedilol; Elasticity Imaging Techniques; Humans; Hypertension, Portal; Liver Cirrhosis; Portal Pre | 2022 |
Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans.
Topics: Aged; Anticoagulants; Antiviral Agents; Ascites; Atorvastatin; Carvedilol; Diuretics; Fibrosis; Huma | 2022 |
[Transudative chylothorax complicated with liver cirrhosis due to primary biliary cholangitis:case report].
Topics: Aged; Bisoprolol; Carvedilol; Chylothorax; Dyspnea; Female; Heart Failure; Humans; Hypertension, Por | 2022 |
Editorial: timing of carvedilol - promoting survivors in cirrhosis.
Topics: Carvedilol; Esophageal and Gastric Varices; Humans; Liver Cirrhosis; Survivors | 2022 |
Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis.
Topics: Adrenergic beta-Antagonists; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage | 2023 |
Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: A national cohort study.
Topics: Adrenergic beta-Antagonists; Carvedilol; Cohort Studies; Hepatitis C; Humans; Liver Cirrhosis; Retro | 2023 |
Carvedilol as Best β-Blocker for Secondary Prophylaxis of Variceal Bleeding: Are We There, or Not Yet?
Topics: Adrenergic beta-Antagonists; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage | 2023 |
Liquid Chromatography-High-Resolution Mass Spectrometry (LC-HRMS) Analysis Following Voluntary Carvedilol Poisoning in a Subject with Cirrhosis: A Case Report.
Topics: Carbazoles; Carvedilol; Chromatography, Liquid; Humans; Liver Cirrhosis; Mass Spectrometry; Propanol | 2023 |
Heart rate variability is associated with disease severity and portal hypertension in cirrhosis.
Topics: Ascites; Carvedilol; Cross-Sectional Studies; Esophageal and Gastric Varices; Heart Rate; Humans; Hy | 2023 |
[Investigate of the etiology and prevention status of liver cirrhosis].
Topics: Carvedilol; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Diseases, Alc | 2023 |
Carvedilol, probably the β-blocker of choice for everyone with cirrhosis and portal hypertension: But not so fast!
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Humans; Hypertension, Portal; Liver Cirrhosis; | 2023 |
Carvedilol in patients with cirrhosis and arterial hypertension: two birds with one stone.
Topics: Adrenergic beta-Antagonists; Carvedilol; Humans; Hypertension; Liver Cirrhosis; Propanolamines | 2023 |
Individualized Treatment of Gastric Varices in Cirrhotic Portal Hypertension.
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hypertension, Porta | 2019 |
Reply.
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Re | 2019 |
Carvedilol Inhibits Angiotensin II-Induced Proliferation and Contraction in Hepatic Stellate Cells through the RhoA/Rho-Kinase Pathway.
Topics: Angiotensin II; Animals; Carbon Tetrachloride Poisoning; Carvedilol; Cell Proliferation; Hepatic Ste | 2019 |
KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications.
Topics: Adrenergic beta-Antagonists; Ammonia; Anti-Bacterial Agents; Carvedilol; Disaccharides; Endoscopy, G | 2020 |
Effects of Carvedilol on the Expression of TLR4 and its Downstream Signaling Pathway in the Liver Tissues of Rats with Cholestatic Liver Fibrosis.
Topics: Adrenergic beta-Antagonists; Animals; Carvedilol; Cholestasis; Liver Cirrhosis; Male; NF-kappa B; Ra | 2020 |
Editorial: Beta blockers and cirrhosis-more than just portal hypertension?
Topics: Adrenergic beta-Antagonists; Carvedilol; Follow-Up Studies; Humans; Hypertension, Portal; Liver Cirr | 2021 |
Editorial: when to start carvedilol in cirrhosis-time to reconsider?
Topics: Carvedilol; Humans; Liver Cirrhosis | 2021 |
Editorial: when to start carvedilol in cirrhosis-time to reconsider? Authors' reply.
Topics: Carvedilol; Humans; Liver Cirrhosis | 2021 |
Carvedilol Attenuates the Progression of Hepatic Fibrosis Induced by Bile Duct Ligation.
Topics: Animals; Bile Ducts; Carbazoles; Carvedilol; Collagen; Gene Expression Regulation; Hepatic Stellate | 2017 |
Reply to: "Carvedilol and survival in cirrhosis with ascites: A cognitive bias?"
Topics: Ascites; Carvedilol; Cognition; Humans; Liver Cirrhosis; Propanolamines | 2017 |
Carvedilol and survival in cirrhosis with ascites: A cognitive bias?
Topics: Ascites; Carvedilol; Cognition; Humans; Liver Cirrhosis; Propanolamines | 2017 |
Did Carvedilol Really Have More Severe Adverse Events than Propranolol in Cirrhotic Patients?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Humans; Liver Cirrhosis; Propanolamines; Propra | 2017 |
Response to Lo et al.
Topics: Carbazoles; Carvedilol; Humans; Liver Cirrhosis; Propanolamines; Propranolol | 2017 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Var | 2017 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Var | 2017 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Var | 2017 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Var | 2017 |
Primary prophylaxis of variceal bleeding.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Endoscopy; Esophageal and Gastric Varices; Gast | 2018 |
Carvedilol attenuates liver fibrosis by suppressing autophagy and promoting apoptosis in hepatic stellate cells.
Topics: Antioxidants; Apoptosis; Autophagy; Carvedilol; Cell Line; Dose-Response Relationship, Drug; Hepatic | 2018 |
Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices.
Topics: Adrenergic beta-Antagonists; Carvedilol; Chemoprevention; Clinical Decision Rules; Elasticity Imagin | 2019 |
Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices.
Topics: Adrenergic beta-Antagonists; Carvedilol; Chemoprevention; Clinical Decision Rules; Elasticity Imagin | 2019 |
Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices.
Topics: Adrenergic beta-Antagonists; Carvedilol; Chemoprevention; Clinical Decision Rules; Elasticity Imagin | 2019 |
Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices.
Topics: Adrenergic beta-Antagonists; Carvedilol; Chemoprevention; Clinical Decision Rules; Elasticity Imagin | 2019 |
Carvedilol Ameliorates Intrahepatic Angiogenesis, Sinusoidal Remodeling and Portal Pressure in Cirrhotic Rats.
Topics: Angiogenesis Inducing Agents; Animals; Capillaries; Carvedilol; Endothelial Cells; Fibronectins; Hum | 2018 |
Addition of Carvedilol to Gastric Variceal Obturation Does Not Decrease Recurrence of Gastric Variceal Bleeding in Patients With Cirrhosis.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carvedilol; Endoscopy, Gastrointestinal | 2019 |
Carvedilol improves liver cirrhosis in rats by inhibiting hepatic stellate cell activation, proliferation, invasion and collagen synthesis.
Topics: Administration, Oral; Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Carb | 2019 |
Carvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway.
Topics: Angiogenesis Inhibitors; Carbazoles; Carvedilol; Cell Movement; Cell Proliferation; Cells, Cultured; | 2015 |
Doxazosin Treatment Attenuates Carbon Tetrachloride-Induced Liver Fibrosis in Hamsters through a Decrease in Transforming Growth Factor β Secretion.
Topics: Adrenergic alpha-1 Receptor Antagonists; Alanine Transaminase; Animals; Aspartate Aminotransferases; | 2016 |
Carvedilol Improves Inflammatory Response, Oxidative Stress and Fibrosis in the Alcohol-Induced Liver Injury in Rats by Regulating Kuppfer Cells and Hepatic Stellate Cells.
Topics: Animals; Biomarkers; Carbazoles; Carvedilol; Chemical and Drug Induced Liver Injury; Cytokines; Dise | 2016 |
Antifibrotic Effects of Carvedilol and Impact of Liver Fibrosis on Carvedilol Pharmacokinetics in a Rat model.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers; Carbazoles; Carvedilol | 2017 |
Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites.
Topics: Adrenergic beta-Antagonists; Aged; Ascites; Carbazoles; Carvedilol; Cause of Death; Female; Humans; | 2017 |
Secondary prophylaxis for variceal bleeding: carvedilol vs. propranolol.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Drug Monitoring; Esophageal and | 2017 |
Carvedilol for portal hypertension in patients with cirrhosis.
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Humans; Hypertension, Portal; Liver Cirrhosis; Male | 2010 |
Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Elasticity; Elasticity Imaging Technique | 2012 |
Carvedilol attenuates the progression of alcohol fatty liver disease in rats.
Topics: Adrenergic beta-Antagonists; Animals; Blood Vessels; Blotting, Western; Carbazoles; Carvedilol; Cent | 2012 |
New therapeutic aspect for carvedilol: antifibrotic effects of carvedilol in chronic carbon tetrachloride-induced liver damage.
Topics: Acute-Phase Proteins; Adrenergic beta-Antagonists; Alanine Transaminase; alpha-Macroglobulins; Anima | 2012 |
Carvedilol: the β-blocker of choice for portal hypertension?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Esophageal and Gastric Varices; Female; Gastroi | 2013 |
Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes.
Topics: Adrenergic beta-Antagonists; Biomarkers; Carbazoles; Carvedilol; E-Selectin; Endothelium, Vascular; | 2006 |
Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Azygos Vein; Blood Flow Velocity; Blood Pressure; | 1996 |
Carvedilol--A new nonselective beta blocker.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Hemodynamics; Humans; Hypotension; Liver Cirrho | 2000 |
An advance in the treatment of portal hypertension?
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Humans; Hypertens | 2000 |